Market Cap 795.43M
Revenue (ttm) 15.93M
Net Income (ttm) -199.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,251.35%
Debt to Equity Ratio -6.42
Volume 492,145
Avg Vol 306,970
Day's Range N/A - N/A
Shares Out 145.95M
Stochastic %K 95%
Beta 0.71
Analysts Strong Sell
Price Target $14.73

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 80 44 75 00
Address:
50 rue de Dijon, Daix, France
POPEYE832
POPEYE832 Jan. 14 at 9:31 AM
$IVA A low-profile Stocktwits board with very few people, a company that’s neither too big nor too small, ignored by the U.S., with no media hype. It reminds me of an ABVX-type scenario, where everyone was left stunned when they saw +500% in the premarket. It now trades at $124, whereas it was worth $5 or $10 at the time.
0 · Reply
POPEYE832
POPEYE832 Jan. 13 at 8:18 PM
$IVA IVA is starting to climb nicely, with Phase 3 results expected in Q2 or Q3 2026. Up 11% on Euronext today, supported by a solid Phase 2 and a Phase 3 with a large sample size. The company will be present at the JPM 2026 conference, is valued at $1 billion on Nasdaq, and it’s starting to smell like a takeover…
0 · Reply
BioRich
BioRich Jan. 12 at 9:10 PM
$ALT Like to share friendly reminders for $ALT Nation every now and again. They sweet to consistently live in a liberal victimhood mindset so sharing truthful reminders is always good. Sent this back in November when there was much discussion about $ALT 48W data and EoP2 meeting. Many were still pumping Biopsies at 48W (yes, the $ALT Pervi's are indeed this dumb). I/we gently reminded y'all that you're in the wrong game. Since then, $ALT is down significantly, $IVA is up significantly (even after it's SP correction for EU trading...don't ask $ALT, you won't understand, it involves numbers and math). Anyway, cheers to $IVA for continued growth. Early cheers to $SNY for your soon to be released acquisition(s). $ALT, you can't get respect if you never do anything to earn it. (Fibrosis Improvement comparison listed in original post below).
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 12 at 8:49 PM
"Leerink was raised to Outperform, triggering a jump-out pull-up - $IVA 🚀 ➤ Short jump +7.04%, the stock price is now +2.67%, and the momentum of the market is obvious. ➤ Relative turnover RVOL 2.46, the transaction heat is higher than average; however, the average daily turnover AVol 0.32M (about 320,000 shares), the liquidity is thin, and the fluctuation is easy to be amplified. ➤ ATR 0.29 shows intraday amplitude amplification, and the fluctuation supports this breakthrough.
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:42 PM
$IVA 07:37 on Jan. 12 2026 Leerink Partners Initiates Coverage On Inventiva with Outperform Rating, Announces Price Target of $12 #tradeideas
0 · Reply
Casparov
Casparov Jan. 9 at 6:10 PM
$IVA Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference next week
0 · Reply
BioRich
BioRich Jan. 9 at 4:09 PM
$ALT Looks like $SGMT is presenting at MASH-TAG tomorrow. I think they should be on this list as well. $IVA, $SGMT and $VKTX should be on this list. I don't believe, with $ALT's miserable Fibrosis Failure, should be on this list. (Note - $ALT FAILED their Fibrosis Improvement Endpoint with the most reliable and effective method approved. PathAI was an AdHoc use for metrics that don't correlate directly to what $ALT failed...something that many continue to miss). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we learn and find these gems (SGMT, IVA, VKTX...not ALT). Let's make some (more) money. Cheers!
1 · Reply
S_Franconi
S_Franconi Jan. 2 at 4:13 PM
$IVA Very Nice!
0 · Reply
S_Franconi
S_Franconi Dec. 29 at 3:16 PM
$IVA In
0 · Reply
BioRich
BioRich Dec. 28 at 5:40 PM
$SNY I believe SNY buys $IVA for the Fibrosis play. If their looking for the hottest play in the Weight Loss sector, they'd snag $GUTS. If you don't know about $GUTS look them up. Big data coming Q1 and should get a boost from $LLY recent news. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!
1 · Reply
Latest News on IVA
Inventiva reports 2025 Third Quarter Financial Information¹

Nov 21, 2025, 4:00 PM EST - 7 weeks ago

Inventiva reports 2025 Third Quarter Financial Information¹


Inventiva announces launch of public offering

Nov 12, 2025, 4:25 PM EST - 2 months ago

Inventiva announces launch of public offering


Inventiva Announces the Implementation of a New ATM Program

Oct 14, 2025, 4:00 PM EDT - 3 months ago

Inventiva Announces the Implementation of a New ATM Program


Inventiva S.A. (IVA) Analyst/Investor Day Transcript

Oct 8, 2025, 7:16 PM EDT - 3 months ago

Inventiva S.A. (IVA) Analyst/Investor Day Transcript


Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Oct 1, 2025, 2:30 AM EDT - 3 months ago

Inventiva Appoints Andrew Obenshain as Chief Executive Officer


Inventiva to Host Analyst and Investor Event on October 8, 2025

Sep 24, 2025, 4:00 PM EDT - 3 months ago

Inventiva to Host Analyst and Investor Event on October 8, 2025


Inventiva receives $10 million milestone payment from CTTQ

Jul 7, 2025, 4:00 PM EDT - 6 months ago

Inventiva receives $10 million milestone payment from CTTQ


Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:30 AM EDT - 8 months ago

Inventiva reports 2025 First Quarter Financial Information¹


Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 10:50 AM EDT - 10 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript


Inventiva reports 2024 Third Quarter Financial Information¹

Nov 21, 2024, 4:00 PM EST - 1 year ago

Inventiva reports 2024 Third Quarter Financial Information¹


POPEYE832
POPEYE832 Jan. 14 at 9:31 AM
$IVA A low-profile Stocktwits board with very few people, a company that’s neither too big nor too small, ignored by the U.S., with no media hype. It reminds me of an ABVX-type scenario, where everyone was left stunned when they saw +500% in the premarket. It now trades at $124, whereas it was worth $5 or $10 at the time.
0 · Reply
POPEYE832
POPEYE832 Jan. 13 at 8:18 PM
$IVA IVA is starting to climb nicely, with Phase 3 results expected in Q2 or Q3 2026. Up 11% on Euronext today, supported by a solid Phase 2 and a Phase 3 with a large sample size. The company will be present at the JPM 2026 conference, is valued at $1 billion on Nasdaq, and it’s starting to smell like a takeover…
0 · Reply
BioRich
BioRich Jan. 12 at 9:10 PM
$ALT Like to share friendly reminders for $ALT Nation every now and again. They sweet to consistently live in a liberal victimhood mindset so sharing truthful reminders is always good. Sent this back in November when there was much discussion about $ALT 48W data and EoP2 meeting. Many were still pumping Biopsies at 48W (yes, the $ALT Pervi's are indeed this dumb). I/we gently reminded y'all that you're in the wrong game. Since then, $ALT is down significantly, $IVA is up significantly (even after it's SP correction for EU trading...don't ask $ALT, you won't understand, it involves numbers and math). Anyway, cheers to $IVA for continued growth. Early cheers to $SNY for your soon to be released acquisition(s). $ALT, you can't get respect if you never do anything to earn it. (Fibrosis Improvement comparison listed in original post below).
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 12 at 8:49 PM
"Leerink was raised to Outperform, triggering a jump-out pull-up - $IVA 🚀 ➤ Short jump +7.04%, the stock price is now +2.67%, and the momentum of the market is obvious. ➤ Relative turnover RVOL 2.46, the transaction heat is higher than average; however, the average daily turnover AVol 0.32M (about 320,000 shares), the liquidity is thin, and the fluctuation is easy to be amplified. ➤ ATR 0.29 shows intraday amplitude amplification, and the fluctuation supports this breakthrough.
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:42 PM
$IVA 07:37 on Jan. 12 2026 Leerink Partners Initiates Coverage On Inventiva with Outperform Rating, Announces Price Target of $12 #tradeideas
0 · Reply
Casparov
Casparov Jan. 9 at 6:10 PM
$IVA Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference next week
0 · Reply
BioRich
BioRich Jan. 9 at 4:09 PM
$ALT Looks like $SGMT is presenting at MASH-TAG tomorrow. I think they should be on this list as well. $IVA, $SGMT and $VKTX should be on this list. I don't believe, with $ALT's miserable Fibrosis Failure, should be on this list. (Note - $ALT FAILED their Fibrosis Improvement Endpoint with the most reliable and effective method approved. PathAI was an AdHoc use for metrics that don't correlate directly to what $ALT failed...something that many continue to miss). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we learn and find these gems (SGMT, IVA, VKTX...not ALT). Let's make some (more) money. Cheers!
1 · Reply
S_Franconi
S_Franconi Jan. 2 at 4:13 PM
$IVA Very Nice!
0 · Reply
S_Franconi
S_Franconi Dec. 29 at 3:16 PM
$IVA In
0 · Reply
BioRich
BioRich Dec. 28 at 5:40 PM
$SNY I believe SNY buys $IVA for the Fibrosis play. If their looking for the hottest play in the Weight Loss sector, they'd snag $GUTS. If you don't know about $GUTS look them up. Big data coming Q1 and should get a boost from $LLY recent news. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!
1 · Reply
BioRich
BioRich Dec. 28 at 5:35 PM
$ALT $SNY $GUTS $IVA $VKTX Don't forget that the ideal blockbuster is $SNY acquiring $GUTS, $IVA and possibly $VKTX. There's your homerun play. $ALT isn't even on the watchlist anymore.
0 · Reply
BioRich
BioRich Dec. 28 at 5:32 PM
$ALT $SNY $IVA $IONS $MDGL Don't forget...
0 · Reply
BioRich
BioRich Dec. 28 at 5:31 PM
$ALT $IVA $SNY $MRK ($ALT is not special and far down the list of possible target)
0 · Reply
BioRich
BioRich Dec. 28 at 5:28 PM
$ALT $MDGL $NVO $IVA (SEE BELOW)
0 · Reply
RatioSignalPro
RatioSignalPro Dec. 27 at 7:21 AM
$IVA Trading dynamics suggest reliability now matters more than momentum bursts. Balance‑sheet flexibility may prove significant. Transparency improvements could narrow valuation spreads. As performance stabilizes, the path forward can strengthen.
1 · Reply
Quantumup
Quantumup Dec. 12 at 7:31 PM
B │ Riley y'day⬆️the PT on $MDGL to $670 from $560, reiterated at a Buy rating and said that they see Rezdiffra peak-year sales of $4.5B $IVA $NVO $VKTX $LLY ALGS SGMT ALT B │Riley said that they now value MASH using a risk-adjusted approach aligned with recent M&A deals, reflecting peak-year sales of $4.5B extended by loss of exclusivity protection and the Rezdiffra/'2086 combo strategy—early GLP-1 adoption trends and strong patient-level script growth support market expansion, while disciplined opex and modest gross-to-net adjustments underpin significant near-term free cash flow generation.
0 · Reply
BioRich
BioRich Dec. 8 at 5:49 PM
$ALT $MDGL @SuperPuncher $ALT's trial convincingly showed minimal effect of Pemvi on Fibrosis improvement (without worsening of MASH). $ALT utilized a very robust biopsy re-read process that is not just the gold standard, but in pure scientific logic proved the observed results to be "true". Note, the same logic would in turn be concrete defense for $ALT and Pemvi if they showed positive differenriation between drug and control. So while I understand your (@superpuncher) post is made to hYpe optimism and hOpe, the true scientific merit remains lacking. $MDGL is currently the leader in MASH (if by nothing else, calendar and revenue generation). $NVO being approved also is a readily available (approved) option that is already engrained by name recognition with providers. If you're looking for the best available drug in trials, look at $IVA . Strong on the data. Strong on the calendar and has existing European ties (which appears increasingly important. Cheers!
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 6 at 4:27 AM
0 · Reply
BioRich
BioRich Dec. 2 at 3:55 AM
$ALT This $ALT board is by far the worst on Stocktwits. $ALT could PR that they are discontinuing ALL trials, are filing for bankcrupt protection, dismissing ALL employees, and this board will spend the evening trying to convince each other that it just means there's a BO for $7B and that there will probably be a PR in the morning. I really don't think the PermaBulls understand how desperate and pitiful you look. Hell, with PermaBull logic/way of thinking, this move could mean that $IVA already has a deal done with $SNY. Truly pitiful. #27Dresses #CINO #WrongJab #PatientSafety #LossOfTrialControl #CEOousted
1 · Reply
Casparov
Casparov Nov. 28 at 8:12 PM
1 · Reply
Shlobby
Shlobby Nov. 26 at 10:13 PM
Long $MIST $KALV $IVA and $SI . Shluld have taken $PHVS alert but out of monies after all these breakouts. Lot is working right now
0 · Reply
Obiwan123
Obiwan123 Nov. 26 at 12:01 PM
$IVA your ceo ruined its shareholders in bluebird. he might do it thr dame here. he sold the company for cheap. he did it know how to run the efficiently. he is hired to bs its shareholders so becareful
0 · Reply